Equillium posts new preclinical EQ504 data supporting ulcerative colitis potential at La Jolla Immunology Conference
EQ•Equillium disclosed preclinical EQ504 findings indicating the program helped preserve intestinal barrier function while dampening inflammation in a lab-based co-culture model; the data were slated for a conference poster presentation on Oct. 6.
1. Preclinical findings
Equillium disclosed new preclinical findings for EQ504, its ulcerative colitis program. The study indicated the compound helped preserve intestinal barrier function while dampening inflammation in a lab-based co-culture model; the results had not yet been presented and were slated for a poster session at La Jolla Immunology on Oct. 6.
